<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">JAMA Netw Open</journal-id><journal-id journal-id-type="iso-abbrev">JAMA Netw Open</journal-id><journal-id journal-id-type="pmc-domain-id">3211</journal-id><journal-id journal-id-type="pmc-domain">jamasd</journal-id><journal-title-group><journal-title>JAMA Network Open</journal-title></journal-title-group><issn pub-type="epub">2574-3805</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>JAMA Network</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC10450571</article-id><article-id pub-id-type="pmcid-ver">PMC10450571.1</article-id><article-id pub-id-type="pmcaid">10450571</article-id><article-id pub-id-type="pmcaiid">10450571</article-id><article-id pub-id-type="pmid">37615989</article-id><article-id pub-id-type="doi">10.1001/jamanetworkopen.2023.29903</article-id><article-id pub-id-type="publisher-id">zoi230858</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="category" specific-use="electronic"><subject>Research</subject></subj-group><subj-group subj-group-type="heading"><subject>Original Investigation</subject></subj-group><subj-group subj-group-type="online-only"><subject>Online Only</subject></subj-group><subj-group subj-group-type="subject-area"><subject>Pulmonary Medicine</subject></subj-group></article-categories><title-group><article-title>Optimizing Longitudinal Tobacco Cessation Treatment in Lung Cancer Screening</article-title><subtitle>A Sequential, Multiple Assignment, Randomized Trial</subtitle><alt-title alt-title-type="headline">Tobacco Cessation Treatment in Lung Cancer Screening</alt-title><alt-title alt-title-type="running-head">Tobacco Cessation Treatment in Lung Cancer Screening</alt-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name name-style="western"><surname>Fu</surname><given-names initials="SS">Steven S.</given-names></name><degrees>MD</degrees><degrees>MSCE</degrees><xref rid="zoi230858aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi230858aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Rothman</surname><given-names initials="AJ">Alexander J.</given-names></name><degrees>PhD</degrees><xref rid="zoi230858aff3" ref-type="aff">
<sup>3</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vock</surname><given-names initials="DM">David M.</given-names></name><degrees>PhD</degrees><xref rid="zoi230858aff4" ref-type="aff">
<sup>4</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Lindgren</surname><given-names initials="BR">Bruce R.</given-names></name><degrees>MS</degrees><xref rid="zoi230858aff5" ref-type="aff">
<sup>5</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Almirall</surname><given-names initials="D">Daniel</given-names></name><degrees>PhD</degrees><xref rid="zoi230858aff6" ref-type="aff">
<sup>6</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Begnaud</surname><given-names initials="A">Abbie</given-names></name><degrees>MD</degrees><xref rid="zoi230858aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Melzer</surname><given-names initials="AC">Anne C.</given-names></name><degrees>MD</degrees><degrees>MS</degrees><xref rid="zoi230858aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi230858aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Schertz</surname><given-names initials="KL">Kelsey L.</given-names></name><degrees>MPH</degrees><xref rid="zoi230858aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Branson</surname><given-names initials="M">Mariah</given-names></name><degrees>BA</degrees><xref rid="zoi230858aff1" ref-type="aff">
<sup>1</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Haynes</surname><given-names initials="D">David</given-names></name><degrees>PhD</degrees><xref rid="zoi230858aff7" ref-type="aff">
<sup>7</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Hammett</surname><given-names initials="P">Patrick</given-names></name><degrees>PhD</degrees><degrees>MA</degrees><xref rid="zoi230858aff1" ref-type="aff">
<sup>1</sup>
</xref><xref rid="zoi230858aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Joseph</surname><given-names initials="AM">Anne M.</given-names></name><degrees>MD</degrees><degrees>MPH</degrees><xref rid="zoi230858aff2" ref-type="aff">
<sup>2</sup>
</xref></contrib></contrib-group><aff id="zoi230858aff1"><label>1</label>Veterans Affairs Health Services Research and Development Center for Care Delivery and Outcomes Research, Minneapolis VA Health Care System, Minneapolis, Minnesota</aff><aff id="zoi230858aff2"><label>2</label>Department of Medicine, University of Minnesota, Minneapolis</aff><aff id="zoi230858aff3"><label>3</label>Department of Psychology, University of Minnesota, Minneapolis</aff><aff id="zoi230858aff4"><label>4</label>Division of Biostatistics, University of Minnesota, Minneapolis</aff><aff id="zoi230858aff5"><label>5</label>Biostatistics Core, Masonic Cancer Center, University of Minnesota, Minneapolis</aff><aff id="zoi230858aff6"><label>6</label>Survey Research Center, Institute for Social Research, University of Michigan, Ann Arbor</aff><aff id="zoi230858aff7"><label>7</label>Institute for Health Informatics, University of Minnesota, Minneapolis</aff><author-notes><title>Article Information</title><p><bold>Accepted for Publication:</bold> July 11, 2023.</p><p content-type="published-online"><bold>Published:</bold> August 24, 2023. doi:<uri content-type="doi">10.1001/jamanetworkopen.2023.29903</uri></p><p content-type="open-access-note"><bold>Open Access:</bold> This is an open access article distributed under the terms of the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://jamanetwork.com/pages/cc-by-license-permissions" ext-link-type="uri">CC-BY License</ext-link>. &#169; 2023 Fu SS et al. <italic toggle="yes">JAMA Network Open</italic>.</p><corresp id="zoi230858cor1"><bold>Corresponding Author:</bold> Steven S. Fu, MD, MSCE, Center for Care Delivery and Outcomes Research (CCDOR), Minneapolis VA Health Care System, One Veterans Drive, 152, Minneapolis, MN 55417 (<email xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="Steven.Fu@va.gov">Steven.Fu@va.gov</email>).</corresp><p content-type="author-contributions"><bold>Author Contributions:</bold> Drs Fu and Joseph had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.</p><p><italic toggle="yes">Concept and design:</italic> Fu, Rothman, Vock, Almiral, Schertz, Branson, Joseph.</p><p><italic toggle="yes">Acquisition, analysis, or interpretation of data:</italic> Fu, Rothman, Vock, Lindgren, Almiral, Begnaud, Melzer, Schertz, Branson, Haynes, Hammett.</p><p><italic toggle="yes">Drafting of the manuscript:</italic> Fu, Vock, Almiral, Schertz, Branson, Haynes, Joseph.</p><p><italic toggle="yes">Critical review of the manuscript for important intellectual content:</italic> Fu, Rothman, Vock, Lindgren, Almiral, Begnaud, Melzer, Schertz, Branson, Hammett.</p><p><italic toggle="yes">Statistical analysis:</italic> Vock, Lindgren, Almiral.</p><p><italic toggle="yes">Obtained funding:</italic> Fu, Rothman, Vock, Almiral, Joseph.</p><p><italic toggle="yes">Administrative, technical, or material support:</italic> Rothman, Almiral, Begnaud, Schertz, Branson, Hammett, Joseph.</p><p><italic toggle="yes">Supervision:</italic> Fu, Melzer, Joseph.</p><p content-type="COI-statement"><bold>Conflict of Interest Disclosures:</bold> Dr Melzer reported receiving grants from Patient-Centered Outcomes Research Institute during the conduct of the study. No other disclosures were reported.</p><p content-type="funding-statement"><bold>Funding/Support:</bold> This study was funded by grant R01CA196873 from the National Cancer Institute. This material is the result of work supported with resources and the use of facilities at the Minneapolis Veterans Affairs Health Services Research and Development Center for Care Delivery and Outcomes Research.</p><p><bold>Role of the Funder/Sponsor:</bold> The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.</p><p><bold>Disclaimer:</bold> The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government.</p><p content-type="data-sharing-statement"><bold>Data Sharing Statement:</bold> See <xref rid="note-ZOI230858-1-s" ref-type="supplementary-material">Supplement 3</xref>.</p><p><bold>Additional Contributions:</bold> We would like to acknowledge the significant contributions to the study from Susan Glaeser and all the coaches and students who participated in counseling and data collection.</p></author-notes><pub-date pub-type="epub" iso-8601-date="2023-08-24T10:00"><day>24</day><month>8</month><year>2023</year></pub-date><pub-date pub-type="collection"><month>8</month><year>2023</year></pub-date><volume>6</volume><issue>8</issue><issue-id pub-id-type="pmc-issue-id">443972</issue-id><elocation-id>e2329903</elocation-id><history><date date-type="received"><day>24</day><month>3</month><year>2023</year></date><date date-type="accepted"><day>11</day><month>7</month><year>2023</year></date></history><pub-history><event event-type="pmc-release"><date><day>24</day><month>08</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>26</day><month>08</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2023-11-02 00:25:21.447"><day>02</day><month>11</month><year>2023</year></date></event></pub-history><permissions><copyright-statement>Copyright 2023 Fu SS et al. <italic toggle="yes">JAMA Network Open</italic>.</copyright-statement><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article distributed under the terms of the CC-BY License.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="jamanetwopen-e2329903.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pdf-version" xlink:href="jamanetwopen-e2329903.pdf">jamanetwopen-e2329903.pdf</self-uri><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="silverchair" xlink:href="https://jamanetwork.com/journals/jamanetworkopen/fullarticle/10.1001/jamanetworkopen.2023.29903"/><abstract abstract-type="key-points"><title>Key Points</title><sec id="ab-zoi230858-1"><title>Question</title><p>Does adding a referral to pharmacy for prescription medication therapy management (MTM) to the evidence-based tobacco longitudinal care (TLC) program improve smoking abstinence rates compared with TLC without MTM among patients who are eligible for lung cancer screening (LCS), who smoke, and who do not respond to early tobacco treatment?</p></sec><sec id="ab-zoi230858-2"><title>Findings</title><p>In this randomized clinical trial of 636 patients who were eligible for LCS and smoked daily, adding a referral to MTM with TLC for participants who did not respond to initial TLC treatment did not improve long-term smoking abstinence (17.8% vs 16.4%).</p></sec><sec id="ab-zoi230858-3"><title>Meaning</title><p>These findings suggest that TLC was most effective when implemented without modification.</p></sec></abstract><abstract abstract-type="teaser" specific-use="electronic"><p>This randomized clinical trial assesses the effect of adding a referral to prescription medication therapy management to the tobacco longitudinal care program among patients eligible for lung cancer screening.</p></abstract><abstract><sec id="ab-zoi230858-4"><title>Importance</title><p>Nearly half of the 14.8 million US adults eligible for lung cancer screening (LCS) smoke cigarettes. The optimal smoking cessation program components for the LCS setting are unclear.</p></sec><sec id="ab-zoi230858-5"><title>Objective</title><p>To assess the effect of adding a referral to prescription medication therapy management (MTM) to the tobacco longitudinal care (TLC) program among patients eligible for LCS who smoke and do not respond to early tobacco treatment and to assess the effect of decreasing the intensity of TLC among participants who do respond to early treatment.</p></sec><sec id="ab-zoi230858-6"><title>Design, Setting, and Participants</title><p>This randomized clinical trial included patients who currently smoked cigarettes daily and were eligible for LCS. Recruitment took place at primary care centers and LCS programs at 3 large health systems in the US and began in October 2016, and 18-month follow-up was completed April 2021.</p></sec><sec id="ab-zoi230858-7"><title>Interventions</title><p>(1) TLC comprising intensive telephone coaching and combination nicotine replacement therapy for 1 year with at least monthly contact; (2) TLC with MTM, MTM offered pharmacist-referral for prescription medications; and (3) Quarterly TLC, intensity of TLC was decreased to quarterly contact. Intervention assignments were based on early response to tobacco treatment (abstinence) that was assessed either 4 weeks or 8 weeks after treatment initiation.</p></sec><sec id="ab-zoi230858-8"><title>Main outcomes and Measures</title><p>Self-reported, 6-month prolonged abstinence at 18-month.</p></sec><sec id="ab-zoi230858-9"><title>Results</title><p>Of 636 participants, 228 (35.9%) were female, 564 (89.4%) were White individuals, and the median (IQR) age was 64.3 (59.6-68.8) years. Four weeks or 8 weeks after treatment initiation, 510 participants (80.2%) continued to smoke (ie, early treatment nonresponders) and 126 participants (19.8%) had quit (ie, early treatment responders). The 18 month follow-up survey response rate was 83.2% (529 of 636). Across TLC groups at 18 months follow-up, the overall 6-month prolonged abstinence rate was 24.4% (129 of 529). Among the 416 early treatment nonresponders, 6-month prolonged abstinence for TLC with MTM vs TLC was 17.8% vs 16.4% (adjusted odds ratio [aOR] 1.13; 95% CI, 0.67-1.89). In TLC with MTM, 98 of 254 participants (39%) completed at least 1 MTM visit. Among 113 early treatment responders, 6-month prolonged abstinence for Quarterly TLC vs TLC was 24 of 55 (43.6%) vs 34 of 58 (58.6%) (aOR, 0.54; 95% CI, 0.25-1.17).</p></sec><sec id="ab-zoi230858-10"><title>Conclusions and Relevance</title><p>In this randomized clinical trial, adding referral to MTM with TLC for participants who did not respond to early treatment did not improve smoking abstinence. Stepping down to Quarterly TLC among early treatment responders is not recommended. Integrating longitudinal tobacco cessation care with LCS is feasible and associated with clinically meaningful quit rates.</p></sec><sec id="ab-zoi230858-11"><title>Trial Registration</title><p>ClinicalTrials.gov Identifier: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://classic.clinicaltrials.gov/ct2/show/NCT02597491" ext-link-type="uri">NCT02597491</ext-link></p></sec></abstract><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="H1-1-ZOI230858"><title>Introduction</title><p>The landmark National Lung Screening Trial demonstrated that annual low-dose computerized tomography (LDCT) for lung cancer screening (LCS) reduces lung cancer death by 20%.<sup><xref rid="zoi230858r1" ref-type="bibr">1</xref>,<xref rid="zoi230858r2" ref-type="bibr">2</xref>,<xref rid="zoi230858r3" ref-type="bibr">3</xref></sup> Since 2013, annual LDCT has been recommended for adults aged 55 to 80 years with a 30 pack-year or more smoking history and who currently smoke or have quit within the past 15 years.<sup><xref rid="zoi230858r4" ref-type="bibr">4</xref>,<xref rid="zoi230858r5" ref-type="bibr">5</xref>,<xref rid="zoi230858r6" ref-type="bibr">6</xref>,<xref rid="zoi230858r7" ref-type="bibr">7</xref></sup> To address lung cancer disparities by sex and race or ethnicity<sup><xref rid="zoi230858r8" ref-type="bibr">8</xref>,<xref rid="zoi230858r9" ref-type="bibr">9</xref></sup> the eligible population was expanded in 2021 to adults aged 50 to 80 years and a 20 pack-year or more smoking history (14.8 million estimated).<sup><xref rid="zoi230858r10" ref-type="bibr">10</xref></sup> About 48% of patients eligible for LCS currently smoke cigarettes.<sup><xref rid="zoi230858r11" ref-type="bibr">11</xref></sup> Annual LCS creates a clinical obligation to develop and implement efficient and effective programs to address smoking in the LCS setting. Furthermore, patients who quit smoking and complete annual LDCT screening experience the greatest mortality reduction.<sup><xref rid="zoi230858r12" ref-type="bibr">12</xref></sup></p><p>Clinical trials have established the efficacy of behavioral treatment, medication treatment, and combination behavioral and medication treatment for long-term smoking cessation.<sup><xref rid="zoi230858r13" ref-type="bibr">13</xref></sup> However, the optimal smoking cessation program components for the LCS setting are unclear.<sup><xref rid="zoi230858r14" ref-type="bibr">14</xref>,<xref rid="zoi230858r15" ref-type="bibr">15</xref></sup> One approach to improving long-term abstinence rates is the use of adaptive interventions. Adaptive interventions describe how to sequence treatment options (such as type, frequency, delivery mode) using information about individuals, including response to previous interventions. For example, for individuals showing early signs of difficulty with quitting, adaptive interventions might dictate which additional treatment to deliver and its timing. Adaptive interventions can also suggest treatment options for individuals who experience early success with quitting.<sup><xref rid="zoi230858r16" ref-type="bibr">16</xref></sup> Interventions that adapt to the changing needs and experiences of the individual are key to the management of chronic diseases like smoking.<sup><xref rid="zoi230858r17" ref-type="bibr">17</xref></sup></p><p>Incorporating chronic care model<sup><xref rid="zoi230858r18" ref-type="bibr">18</xref>,<xref rid="zoi230858r19" ref-type="bibr">19</xref></sup> principles, the Tobacco Longitudinal Care (TLC) program is tobacco treatment comprised of intensive telephone coaching and combination nicotine replacement therapy (NRT).<sup><xref rid="zoi230858r17" ref-type="bibr">17</xref></sup> A unique feature of TLC is that the program encourages participants who relapse to set a new quit date and if they are unwilling to do so, to try to reduce their smoking in anticipation of setting a new quit date.</p><p>TLC delivered for 1 year was previously demonstrated to be efficacious in a confirmatory, randomized clinical trial.<sup><xref rid="zoi230858r17" ref-type="bibr">17</xref></sup> The current study reports the main results of the Program for Lung Cancer Screening and Tobacco Cessation (PLUTO) trial.<sup><xref rid="zoi230858r20" ref-type="bibr">20</xref></sup> PLUTO was designed to test different adaptive interventions based on TLC, which health systems could implement to address smoking in the LCS setting. The PLUTO trial participates in the Smoking Cessation at Lung Examination (SCALE) collaboration sponsored by the National Cancer Institute (NCI), a set of clinical trials evaluating smoking cessation interventions delivered in the LCS setting.<sup><xref rid="zoi230858r21" ref-type="bibr">21</xref></sup></p><p>PLUTO used a 2-stage, sequential, multiple assignment, randomized trial (SMART) design.<sup><xref rid="zoi230858r22" ref-type="bibr">22</xref>,<xref rid="zoi230858r23" ref-type="bibr">23</xref>,<xref rid="zoi230858r24" ref-type="bibr">24</xref></sup> SMART trials are not confirmatory randomized trials; rather, they are designed to provide evidence for how best to construct an adaptive intervention.<sup><xref rid="zoi230858r25" ref-type="bibr">25</xref></sup> The primary aim was to assess the effect of adding referral to prescription medication therapy management (MTM) to TLC among participants who did not respond early to smoking cessation treatment (hereafter referred to as early treatment nonresponders, defined as any smoking, even a puff, in the last 7 days).<sup><xref rid="zoi230858r26" ref-type="bibr">26</xref></sup> We hypothesized that among early treatment nonresponders, long-term abstinence rates (primary outcome) would be higher in participants randomized to TLC with MTM compared with TLC alone without MTM. Our secondary aim assessed the effect of decreasing the intensity of the TLC program from at least monthly contact to at least quarterly contact among participants who did respond to early treatment (hereafter referred to as early treatment responders, defined as no smoking, even a puff, in the last 7 days). We hypothesized that more intensive follow-up would improve long-term abstinence rates.</p></sec><sec id="H1-2-ZOI230858"><title>Methods</title><sec id="H2-1-ZOI230858"><title>Study Design Overview</title><p>The PLUTO trial was approved by the institutional review boards at the University of Minnesota, the Minneapolis Veterans Affairs Health Care System, and the Allina Health System. Written informed consent was obtained. The study protocol and methods have been previously described (<xref rid="note-ZOI230858-1-s" ref-type="supplementary-material">Supplement 1</xref>).<sup><xref rid="zoi230858r20" ref-type="bibr">20</xref></sup> Participants received 1 of 3 TLC-based interventions based on defined decision rules (<xref rid="zoi230858f1" ref-type="fig">Figure 1</xref>) for 1 year. Each participant was randomized twice. In stage 1, all participants initiated TLC and were randomized to assess early response to TLC treatment at either 4 weeks vs 8 weeks (randomization 1, the results of which are not included in this article). In stage 2, participants were randomized to different interventions. Early treatment nonresponders were randomized to continue TLC with a minimum of monthly contact or TLC with MTM (randomization 2A). MTM provided access to prescription medications delivered by a pharmacist with prescribing privileges. Early treatment responders were randomized to continue TLC with a minimum of monthly contact or TLC with less intensive quarterly contact (Quarterly TLC; randomization 2B). PLUTO started recruitment October 2016 and completed the 18-month survey in April 2021 during the COVID-19 pandemic. Electronic medical record (EMR) data extraction, data cleaning, and analysis occurred from June 2021 to December 2022.</p><fig position="float" id="zoi230858f1" fig-type="figure" orientation="portrait"><label>Figure 1. </label><caption><title>Sequential, Multiple Assignment, Randomized TrialDesign</title><p>MTM indicates medication therapy management; TLC, tobacco longitudinal care; TLC&#8201;+&#8201;MTM, tobacco longitudinal care with medication therapy management.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamanetwopen-e2329903-g001.jpg"/></fig></sec><sec id="H2-2-ZOI230858"><title>Study Participants</title><p>Inclusion criteria were having LDCT for LCS scheduled or ordered or being LCS eligible, currently smoking daily, being 55 to 80 years old, and being willing to choose a quit date within the next 12 weeks. Exclusion criteria were having an unstable psychiatric disease or cognitive impairment, currently participating in smoking cessation treatment, not having a phone, or not speaking English.</p></sec><sec id="H2-3-ZOI230858"><title>Interventions</title><sec id="H3-1-ZOI230858"><title>TLC</title><p>TLC is a counseling-based intervention formulated on a chronic care model for tobacco treatment, including recycling treatment tools and relapse prevention. The TLC protocol<sup><xref rid="zoi230858r16" ref-type="bibr">16</xref>,<xref rid="zoi230858r17" ref-type="bibr">17</xref></sup> includes contingencies for whether participants are abstinent, have relapsed but reduced smoking, have resumed the original amount of smoking, or have not quit at all.</p><p>Six scheduled counseling calls were provided during the first 4 weeks and a seventh call at week 8. After this initial sequence of calls, participants were contacted at least monthly by their coach, but the frequency of calls may have been higher around quit dates after relapse. The focus of counseling was cessation. Combination NRT was recommended<sup><xref rid="zoi230858r27" ref-type="bibr">27</xref></sup> and mailed free of charge by the coach.</p></sec><sec id="H3-2-ZOI230858"><title>TLC With MTM</title><p>In TLC with MTM, TLC was expanded to include referral and consultation with a pharmacist to prescribe bupropion, varenicline, nicotine spray, nicotine inhaler, or combination medications (eg, bupropion with NRT). Because this was a pragmatic trial, participants could decline referral. If referred, participants were not obliged to use medications, but pharmacists promoted their use. Prescribed medications were covered by participant&#8217;s health insurance. The first visit with the pharmacist was in-person, if possible, and about 1 hour in duration. Typically, 3 to 6 follow-up phone calls (5 to 10 minutes duration) were offered throughout a 12-week period but depended on participant interest and progress. The pharmacist was available until the end of the 1-year intervention period. While the TLC counselor continued to interact with the participant during MTM, the pharmacist had primary responsibility for medication management.</p></sec><sec id="H3-3-ZOI230858"><title>Quarterly TLC</title><p>Early treatment responders were assigned to receive continued TLC or Quarterly TLC and counselors called participants every 3 months for 1 year. They provided the same coaching options as TLC, but on a less intensive schedule. Participants could initiate additional calls.</p></sec></sec><sec id="H2-4-ZOI230858"><title>Research Data Sources and Data Collection</title><p>Data sources included telephone surveys, the EMR, and counselor records. PLUTO provided financial incentives for completing research surveys ($20 to $25) but not for treatment participation. Research assistants involved in data collection were blinded to intervention assignments.</p></sec><sec id="H2-5-ZOI230858"><title>Outcome Measures</title><p>The primary outcome was self-reported, 6-month prolonged abstinence at 18 months<sup><xref rid="zoi230858r26" ref-type="bibr">26</xref></sup>; smoking at least once on 7 consecutive days or at least once on 2 consecutive weekends in the 6-month period defined nonabstinence. Initial biochemical verification of smoking abstinence with salivary cotinine was disrupted by the COVID-19 pandemic in March 2020. In May 2020, we attempted to use CO (carbon monoxide) smokelyzers to verify smoking abstinence<sup><xref rid="zoi230858r28" ref-type="bibr">28</xref></sup>; however, product availability was limited and the data safety and management board approved a protocol change to self-reported 6-month prolonged abstinence as the primary outcome. Secondary outcomes included 7-day point prevalence abstinence at 12 months and 18 months; any smoking in the past 7 days, even a puff, defined nonabstinence.</p></sec><sec id="H2-6-ZOI230858"><title>Sample Size and Power Analysis</title><p>The sample size was chosen to ensure sufficient statistical power for the primary outcome, comparing TLC with TLC with MTM among early treatment nonresponders. Sample size formula for the number of early treatment nonresponders needed for the primary analysis was equivalent to standard calculations for 2-group randomized trials. We reestimated the sample size in April 2019 using blinded data to estimate the proportion of early treatment nonresponders and proportion achieving prolonged abstinence across both groups. Seven hundred participants provided approximately 90% power to detect a 10% difference in 6-month prolonged abstinence between TLC and TLC with MTM, assuming 80% of the sample would be early treatment nonresponders and 10% would achieve prolonged abstinence with TLC.</p></sec><sec id="H2-7-ZOI230858"><title>Statistical Analysis</title><p>All analyses were intention-to-treat (ITT). All hypothesis tests were 2-sided with <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.05 considered statistically significant. Baseline characteristics were summarized overall and by the 2 comparison groups for the primary aim (defined by randomization 2A) and by the 2 comparisons groups for the secondary aim (defined by randomization 2B). To assess the primary aim (comparison of TLC with MTM vs TLC) we fit logistic regression models among early treatment nonresponders with covariates for age, baseline cigarettes per day, site, timing of assessment to early treatment (4-week vs 8-week assessment), in addition to an indicator for TLC with MTM vs TLC. A similar set of logistic regression models among early treatment responders were fit to assess secondary aim 1 (comparison of TLC to Quarterly TLC). The amount of treatment delivered was summarized by the frequencies or the median. Comparisons between randomized groups were conducted by &#967;<sup>2</sup> or Wilcoxon rank-sum test. We addressed missing data using multiple imputation for the primary outcome and reported complete cases and additional sensitivity analyses for secondary outcomes (eTable in <xref rid="note-ZOI230858-1-s" ref-type="supplementary-material">Supplement 2</xref>).</p></sec></sec><sec id="H1-3-ZOI230858"><title>Results</title><p>The ITT sample used for data analysis included 636 participants. The CONSORT<sup><xref rid="zoi230858r29" ref-type="bibr">29</xref></sup> diagram is shown in <xref rid="zoi230858f2" ref-type="fig">Figure 2</xref>. Of 1236 individuals screened, 982 were eligible, 691 consented, and 636 completed an outreach call and were randomized. After stage 1, 510 were early treatment nonresponders (80.2%) and 126 (19.8%) were early treatment responders. Data collection completion rates at 4, 8, 12, 26, 52, and 78 weeks (primary end point) for the 636 participants were 92.1% (586 participants), 90.6% (576 participants), 89.3% (568 participants), 85.8% (546 participants), 85.4% (543 participants), and 83.2% (529 participants), respectively.</p><fig position="float" id="zoi230858f2" fig-type="figure" orientation="portrait"><label>Figure 2. </label><caption><title>Study Flow Diagram</title><p>MTM indicates medication therapy management; TLC, tobacco longitudinal care.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="jamanetwopen-e2329903-g002.jpg"/></fig><sec id="H2-8-ZOI230858"><title>Baseline Characteristics</title><p>Baseline characteristics are presented in <xref rid="zoi230858t1" ref-type="table">Table 1</xref>. The median (IQR) age of participants was 64.3 (59.6-68.8) years and 228 (35.9%) of the cohort was female. Median (IQR) cigarettes per day was 20.0 (10-20), and 485 participants (76.3%) smoked within 30 minutes of waking. Median (IQR) pack-years was 47.1 (36.3-59.8), and 271 (42.6%) had tried to quit in the past year. Most participants had previously tried NRT (542 [85.2%]) and prescription cessation medications (379 [59.6%]).</p><table-wrap position="float" id="zoi230858t1" orientation="portrait"><label>Table 1. </label><caption><title>Selected Baseline Characteristics by TLC Intervention Group (N&#8201;=&#8201;636)<sup>a</sup></title></caption><table frame="hsides" rules="groups"><col width="24.35%" span="1"/><col width="16.7%" span="1"/><col width="22.04%" span="1"/><col width="16.1%" span="1"/><col width="20.81%" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Characteristics</th><th colspan="4" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No (%) (N&#8201;=&#8201;636)</th></tr><tr><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Randomization 2A: primary aim</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Randomization 2B: secondary aim</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">TLC (n&#8201;=&#8201;256)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">TLC&#8201;+&#8201;MTM (n&#8201;=&#8201;254)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">TLC (n&#8201;=&#8201;64)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Quarterly TLC (n&#8201;=&#8201;62)</th></tr></thead><tbody><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Age, median (IQR), y</td><td valign="top" align="left" rowspan="1" colspan="1">63.1 (58.9-68.5)</td><td valign="top" align="left" rowspan="1" colspan="1">64.4 (59.8-68.6)</td><td valign="top" align="left" rowspan="1" colspan="1">66.0 (60.2-69.8)</td><td valign="top" align="left" rowspan="1" colspan="1">66.1 (60.7-69.7)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Sex</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Female</td><td valign="top" align="left" rowspan="1" colspan="1">92 (35.9)</td><td valign="top" align="left" rowspan="1" colspan="1">97 (38.2)</td><td valign="top" align="left" rowspan="1" colspan="1">21 (32.8)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (31.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Male</td><td valign="top" align="left" rowspan="1" colspan="1">164 (64.1)</td><td valign="top" align="left" rowspan="1" colspan="1">157 (61.8)</td><td valign="top" align="left" rowspan="1" colspan="1">43 (67.2)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (69.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Race</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Black</td><td valign="top" align="left" rowspan="1" colspan="1">12 (4.7)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (6.4)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> White</td><td valign="top" align="left" rowspan="1" colspan="1">226 (88.6)</td><td valign="top" align="left" rowspan="1" colspan="1">220 (88.0)</td><td valign="top" align="left" rowspan="1" colspan="1">62 (96.9)</td><td valign="top" align="left" rowspan="1" colspan="1">118 (93.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Other<sup>b</sup></td><td valign="top" align="left" rowspan="1" colspan="1">17 (6.7)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (5.6)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">4 (3.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Ethnicity</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">3 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Non-Hispanic</td><td valign="top" align="left" rowspan="1" colspan="1">253 (98.8)</td><td valign="top" align="left" rowspan="1" colspan="1">249 (98.8)</td><td valign="top" align="left" rowspan="1" colspan="1">64 (100.0)</td><td valign="top" align="left" rowspan="1" colspan="1">62 (100.0)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Education</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> High school graduate or less</td><td valign="top" align="left" rowspan="1" colspan="1">86 (33.7)</td><td valign="top" align="left" rowspan="1" colspan="1">94 (37.0)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (28.1)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (32.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Vocational training or some college</td><td valign="top" align="left" rowspan="1" colspan="1">110 (43.1)</td><td valign="top" align="left" rowspan="1" colspan="1">110 (43.3)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (46.9)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (43.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bachelor&#8217;s or graduate degree</td><td valign="top" align="left" rowspan="1" colspan="1">59 (23.1)</td><td valign="top" align="left" rowspan="1" colspan="1">50 (19.7)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (25.0)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (23.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Marital status, married or living with partner</td><td valign="top" align="left" rowspan="1" colspan="1">115 (45.3)</td><td valign="top" align="left" rowspan="1" colspan="1">107 (42.1)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (48.4)</td><td valign="top" align="left" rowspan="1" colspan="1">67 (53.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Household income</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &lt;$15&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">31 (13.0)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (15.2)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (15.3)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (12.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> $15&#8201;000-$34&#8201;999</td><td valign="top" align="left" rowspan="1" colspan="1">52 (21.8)</td><td valign="top" align="left" rowspan="1" colspan="1">62 (27.0)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (22.0)</td><td valign="top" align="left" rowspan="1" colspan="1">23 (20.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> $35&#8201;000-$64&#8201;999</td><td valign="top" align="left" rowspan="1" colspan="1">69 (28.9)</td><td valign="top" align="left" rowspan="1" colspan="1">68 (29.6)</td><td valign="top" align="left" rowspan="1" colspan="1">15 (25.4)</td><td valign="top" align="left" rowspan="1" colspan="1">35 (30.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> $65&#8201;000-$100&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">58 (24.3)</td><td valign="top" align="left" rowspan="1" colspan="1">40 (17.4)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (27.1)</td><td valign="top" align="left" rowspan="1" colspan="1">28 (24.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> &gt;$100&#8201;000</td><td valign="top" align="left" rowspan="1" colspan="1">29 (12.1)</td><td valign="top" align="left" rowspan="1" colspan="1">25 (10.9)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (12.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">CPD, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">19.5 (10.0-20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">20.0 (11.0-20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">15.0 (10.0-20.0)</td><td valign="top" align="left" rowspan="1" colspan="1">15.0 (10.0-20.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Smoking within 30 min of waking</td><td valign="top" align="left" rowspan="1" colspan="1">201 (85.2)</td><td valign="top" align="left" rowspan="1" colspan="1">202 (95.5)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (64.1)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (66.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Pack-years, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">45.2 (34.9-58.1)</td><td valign="top" align="left" rowspan="1" colspan="1">48.5 (38.7-66.6)</td><td valign="top" align="left" rowspan="1" colspan="1">46.5 (31.7-55.2)</td><td valign="top" align="left" rowspan="1" colspan="1">46.9 (37.0-54.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Use e-cigarettes, every day or some days</td><td valign="top" align="left" rowspan="1" colspan="1">20 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">14 (5.5)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3.2)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Use marijuana, every day or some days</td><td valign="top" align="left" rowspan="1" colspan="1">53 (20.8)</td><td valign="top" align="left" rowspan="1" colspan="1">45 (17.7)</td><td valign="top" align="left" rowspan="1" colspan="1">13 (20.3)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (19.4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Tried quitting past 12 mos</td><td valign="top" align="left" rowspan="1" colspan="1">93 (36.3)</td><td valign="top" align="left" rowspan="1" colspan="1">111 (43.7)</td><td valign="top" align="left" rowspan="1" colspan="1">34 (53.1)</td><td valign="top" align="left" rowspan="1" colspan="1">33 (53.2)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Tobacco quit programs</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> In-person 1-on-1 counseling</td><td valign="top" align="left" rowspan="1" colspan="1">37 (14.5)</td><td valign="top" align="left" rowspan="1" colspan="1">38 (15.0)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (15.6)</td><td valign="top" align="left" rowspan="1" colspan="1">10 (16.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> In-person group counseling</td><td valign="top" align="left" rowspan="1" colspan="1">30 (11.7)</td><td valign="top" align="left" rowspan="1" colspan="1">27 (10.6)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (9.4)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (11.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Telephone help or quit line</td><td valign="top" align="left" rowspan="1" colspan="1">50 (19.6)</td><td valign="top" align="left" rowspan="1" colspan="1">63 (24.8)</td><td valign="top" align="left" rowspan="1" colspan="1">12 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (11.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Internet program or phone app</td><td valign="top" align="left" rowspan="1" colspan="1">10 (3.9)</td><td valign="top" align="left" rowspan="1" colspan="1">8 (3.2)</td><td valign="top" align="left" rowspan="1" colspan="1">0</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Used any form of NRT in the past</td><td valign="top" align="left" rowspan="1" colspan="1">216 (84.4)</td><td valign="top" align="left" rowspan="1" colspan="1">218 (85.8)</td><td valign="top" align="left" rowspan="1" colspan="1">53 (82.8)</td><td valign="top" align="left" rowspan="1" colspan="1">55 (88.7)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Used prescription cessation medications in the past</td><td valign="top" align="left" rowspan="1" colspan="1">150 (58.6)</td><td valign="top" align="left" rowspan="1" colspan="1">154 (60.6)</td><td valign="top" align="left" rowspan="1" colspan="1">34 (53.1)</td><td valign="top" align="left" rowspan="1" colspan="1">41 (66.1)</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Health status (SF-12), general health</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Excellent</td><td valign="top" align="left" rowspan="1" colspan="1">9 (3.5)</td><td valign="top" align="left" rowspan="1" colspan="1">3 (1.2)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">5 (8.1)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Very good</td><td valign="top" align="left" rowspan="1" colspan="1">61 (23.8)</td><td valign="top" align="left" rowspan="1" colspan="1">53 (20.9)</td><td valign="top" align="left" rowspan="1" colspan="1">11 (17.2)</td><td valign="top" align="left" rowspan="1" colspan="1">16 (25.8)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Good</td><td valign="top" align="left" rowspan="1" colspan="1">91 (35.6)</td><td valign="top" align="left" rowspan="1" colspan="1">103 (40.6)</td><td valign="top" align="left" rowspan="1" colspan="1">31 (48.4)</td><td valign="top" align="left" rowspan="1" colspan="1">22 (35.5)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Fair</td><td valign="top" align="left" rowspan="1" colspan="1">74 (28.9)</td><td valign="top" align="left" rowspan="1" colspan="1">69 (27.2)</td><td valign="top" align="left" rowspan="1" colspan="1">17 (26.6)</td><td valign="top" align="left" rowspan="1" colspan="1">18 (29.0)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Poor</td><td valign="top" align="left" rowspan="1" colspan="1">21 (8.2)</td><td valign="top" align="left" rowspan="1" colspan="1">26 (10.2)</td><td valign="top" align="left" rowspan="1" colspan="1">4 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.6)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Charlson Comorbidity Index, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (2.0-5.0)</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (2-5)</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (2-5)</td><td valign="top" align="left" rowspan="1" colspan="1">3.0 (2-4)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Self-reported LDCT lung cancer screening</td><td valign="top" align="left" rowspan="1" colspan="1">179 (69.9)</td><td valign="top" align="left" rowspan="1" colspan="1">184 (72.4)</td><td valign="top" align="left" rowspan="1" colspan="1">49 (76.6)</td><td valign="top" align="left" rowspan="1" colspan="1">53 (85.5)</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: CPD, cigarettes per day; LDCT, low-dose computerized tomography; MTM, medication therapy management; NRT, nicotine replacement therapy; SF-12, 12-Item Short Form Health Survey; TLC, tobacco longitudinal care; TLC + MTM, tobacco longitudinal care with medication therapy management.</p><fn id="zoi230858t1n1"><label>
<sup>a</sup>
</label><p>N&#8201;=&#8201;622 to 636, depending on the baseline characteristic.</p></fn><fn id="zoi230858t1n2"><label>
<sup>b</sup>
</label><p>Other includes Asian individuals, Native Hawaiian or Pacific Islander individuals, American Indian or Alaska Native individuals.</p></fn></table-wrap-foot></table-wrap></sec><sec id="H2-9-ZOI230858"><title>Abstinence Outcomes</title><p>The 18 month follow-up survey response rate was 83.2% (529 of 636 participants). Across TLC intervention groups, at week 78 (6 months after the end of the intervention), the overall 6-month prolonged smoking abstinence rate was 24.4% (129 of 529 participants) and the overall 7-day point prevalence smoking abstinence rate was 36.1% (191 of 529 participants). Abstinence rates by TLC intervention group are shown in <xref rid="zoi230858t2" ref-type="table">Table 2</xref>. Primary outcome data were missing in 107 participants (16.8%). In the primary analysis using multiple imputation among early treatment nonresponders at week 78, 37 of 208 participants (17.8%) in TLC with MTM self-reported 6-month prolonged abstinence compared with 34 of 208 participants (16.4%) in TLC (adjusted odds ratio [aOR], 1.13; 95% CI, 0.67-1.89; <italic toggle="yes">P</italic>&#8201;=&#8201;.66). A complete case analysis (n&#8201;=&#8201;416) showed similar results (aOR, 1.11; 95% CI, 0.66-1.86). A third analysis assuming that participants with missing data were continuing to smoke showed comparable results (aOR, 1.11; 95% CI, 0.67-1.85). Seven-day point prevalent abstinence for TLC with MTM was 62 of 208 (29.8%) compared with 57 of 208 (27.4%) in TLC (aOR, 1.14; 95% CI, 0.74-1.74).</p><table-wrap position="float" id="zoi230858t2" orientation="portrait"><label>Table 2. </label><caption><title>Observed and Adjusted Abstinence Rates and Sensitivity Analyses</title></caption><table frame="hsides" rules="groups"><col width="19%" span="1"/><col width="13.12%" span="1"/><col width="18.79%" span="1"/><col width="15.29%" span="1"/><col width="16.97%" span="1"/><col width="16.83%" span="1"/><thead><tr><th rowspan="2" valign="top" align="left" scope="col" colspan="1">Participant group</th><th colspan="2" valign="top" align="left" scope="colgroup" rowspan="1">Participants, observed proportion (unadjusted), complete case analysis, No. (%) (n&#8201;=&#8201;416)<xref rid="zoi230858t2n1" ref-type="table-fn"><sup>a</sup></xref></th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Adjusted odds ratio, TLC+MTM compared with TLC (95% CI)</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">TLC</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">TLC&#8201;+&#8201;MTM</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Complete case analysis (n&#8201;=&#8201;416)<xref rid="zoi230858t2n1" ref-type="table-fn"><sup>a</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Assuming missing&#8201;=&#8201;smoking analysis (n&#8201;=&#8201;500)<xref rid="zoi230858t2n1" ref-type="table-fn"><sup>a</sup></xref></th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Multiple imputation analysis (n&#8201;=&#8201;500)<xref rid="zoi230858t2n2" ref-type="table-fn"><sup>b</sup></xref></th></tr></thead><tbody><tr><td colspan="6" valign="top" align="left" scope="col" rowspan="1">
<bold>Early treatment nonresponders</bold>
</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Week 78: 6-mo prolonged abstinence</td><td valign="top" align="left" rowspan="1" colspan="1">34/208 (16.4)</td><td valign="top" align="left" rowspan="1" colspan="1">37/208 (17.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.11 (0.66-1.86)</td><td valign="top" align="left" rowspan="1" colspan="1">1.11 (0.67-1.85)</td><td valign="top" align="left" rowspan="1" colspan="1">1.13 (0.67-1.89)<xref rid="zoi230858t2n3" ref-type="table-fn"><sup>c</sup></xref></td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Week 78: 7-d point-prevalent abstinence</td><td valign="top" align="left" rowspan="1" colspan="1">57/208 (27.4)</td><td valign="top" align="left" rowspan="1" colspan="1">62/208 (29.8)</td><td valign="top" align="left" rowspan="1" colspan="1">1.14 (0.74-1.74)</td><td valign="top" align="left" rowspan="1" colspan="1">1.09 (0.76-1.56)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1">Week 52 (end of treatment): 7-d point-prevalent abstinence</td><td valign="top" align="left" rowspan="1" colspan="1">57/216 (26.4)</td><td valign="top" align="left" rowspan="1" colspan="1">58/216 (26.9)</td><td valign="top" align="left" rowspan="1" colspan="1">1.03 (0.67-1.60)</td><td valign="top" align="left" rowspan="1" colspan="1">0.97 (0.67-1.41)</td><td valign="top" align="left" rowspan="1" colspan="1">NA</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: TLC, tobacco longitudinal care; TLC + MTM, tobacco longitudinal care&#8201;+&#8201;medication therapy management.</p><fn id="zoi230858t2n1"><label>
<sup>a</sup>
</label><p>At Week 78 data were collected from 416 participants, at Week 52 data were collected from 432 participants.</p></fn><fn id="zoi230858t2n2"><label>
<sup>b</sup>
</label><p>Primary outcome with deaths excluded. An additional sensitivity analysis including deaths showed similar results.</p></fn><fn id="zoi230858t2n3"><label>
<sup>c</sup>
</label><p><italic toggle="yes">P</italic>&#8201;=&#8201;.66.</p></fn></table-wrap-foot></table-wrap><p>Among early treatment responders at week 78, 24 of 55 participants (43.6%) in Quarterly TLC reported 6-month prolonged abstinence compared with 34 of 58 (58.6%) in TLC (aOR, 0.54; 95% CI, 0.25-1.17). For Quarterly TLC, 32 of 55 participants (58.2%) had a 7-day point prevalent abstinence compared with 40 of 58 participants (69.0%) for TLC (aOR, 0.64; 95% CI, 0.29-1.40).</p><p>Only 79 of 141 (56%) saliva or CO kits that were sent out during the trial were returned; thus there is limited data regarding the biochemical verification of self-reported abstinence. Of the 59 participants who reported abstinence, 45 (76.3%) were biochemically confirmed, and there were not significant differences between comparison groups.</p></sec><sec id="H2-10-ZOI230858"><title>Treatment Delivered</title><p><xref rid="zoi230858t3" ref-type="table">Table 3</xref> summarizes coaching and medication treatment delivered to participants. Most participants received combination NRT (range, 82.3%-89.1% across TLC groups); there were no significant differences between groups. Additionally, 116 of 254 participants (45.7%) assigned to MTM accepted referral to MTM, and 98 of 254 (38.6%) completed at least 1 visit. The median (IQR) number of pharmacy visits per participant for those who completed at least 1 MTM visit was 6.5 (3.0 to 10.0) visits. Significantly more early treatment nonresponders received any prescription medications in TLC with MTM compared with TLC (86/256 [33.9%] vs 48/256 [18.8%]; <italic toggle="yes">P</italic>&#8201;&lt;&#8201;.001), but among early treatment responders the difference in receipt of prescription medications between TLC and Quarterly TLC was not significant (4/64 [6.3%] vs 9/62 [14.5%]; <italic toggle="yes">P</italic>&#8201;=&#8201;.15). There was no significant difference in the median (IQR) number of coaching calls between TLC and TLC with MTM (12.0 [9.5-15.0] calls vs 12.0 [7.5-15.0] calls), or between TLC and Quarterly TLC (12.0 [8.0-15.0] calls vs 12.0 [9.0-14.0] calls).</p><table-wrap position="float" id="zoi230858t3" orientation="portrait"><label>Table 3. </label><caption><title>Coaching and Medication Treatment Delivered Over 12 Months</title></caption><table frame="hsides" rules="groups"><col width="25.33%" span="1"/><col width="13.05%" span="1"/><col width="17.26%" span="1"/><col width="9.17%" span="1"/><col width="11.29%" span="1"/><col width="15.06%" span="1"/><col width="8.84%" span="1"/><thead><tr><th rowspan="3" valign="top" align="left" scope="col" colspan="1">Treatment</th><th colspan="6" valign="top" align="left" scope="colgroup" rowspan="1">Participants, No (%)</th></tr><tr><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Early treatment nonresponders: randomization 2A</th><th colspan="3" valign="top" align="left" scope="colgroup" rowspan="1">Early treatment responders: randomization 2B</th></tr><tr><th valign="top" colspan="1" align="left" scope="colgroup" rowspan="1">TLC (n&#8201;=&#8201;256)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">TLC&#8201;+&#8201;MTM (n&#8201;=&#8201;254)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">TLC (n&#8201;=&#8201;64)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1">Quarterly TLC (n&#8201;=&#8201;62)</th><th valign="top" align="left" scope="col" rowspan="1" colspan="1"><italic toggle="yes">P</italic> value</th></tr></thead><tbody><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Coaching</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. coaching calls, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">12.0 (7.5-15)</td><td valign="top" align="left" rowspan="1" colspan="1">12.0 (8-15)</td><td valign="top" align="left" rowspan="1" colspan="1">.15</td><td valign="top" align="left" rowspan="1" colspan="1">12.0 (9.5-15)</td><td valign="top" align="left" rowspan="1" colspan="1">12.0 (9-14)</td><td valign="top" align="left" rowspan="1" colspan="1">.72</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Total duration of calls, median (IQR), min</td><td valign="top" align="left" rowspan="1" colspan="1">130.5 (86.5-170.5)</td><td valign="top" align="left" rowspan="1" colspan="1">133.0 (92-182)</td><td valign="top" align="left" rowspan="1" colspan="1">.19</td><td valign="top" align="left" rowspan="1" colspan="1">127.5 (98-170)</td><td valign="top" align="left" rowspan="1" colspan="1">131.5 (98-197)</td><td valign="top" align="left" rowspan="1" colspan="1">.45</td></tr><tr><td valign="top" align="left" scope="col" rowspan="1" colspan="1">Medications</td><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/><td valign="top" align="left" rowspan="1" colspan="1"/></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Single NRT only over 12 mos of treatment (patch, lozenge, or gum)</td><td valign="top" align="left" rowspan="1" colspan="1">36 (14.1)</td><td valign="top" align="left" rowspan="1" colspan="1">30 (11.8)</td><td rowspan="3" valign="middle" align="left" colspan="1">.51</td><td valign="top" align="left" rowspan="1" colspan="1">5 (7.8)</td><td valign="top" align="left" rowspan="1" colspan="1">6 (9.7)</td><td rowspan="3" valign="middle" align="left" colspan="1">.76</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> No. of weeks NRT provided, median (IQR)</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (2-8)</td><td valign="top" align="left" rowspan="1" colspan="1">6.0 (2-16)</td><td valign="top" colspan="1" align="left" rowspan="1">6.0 (2-10)</td><td valign="top" align="left" rowspan="1" colspan="1">7.0 (2-38)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> More than 1 NRT (patch, lozenge, gum) over 12 mos of treatment</td><td valign="top" align="left" rowspan="1" colspan="1">211 (82.4)</td><td valign="top" align="left" rowspan="1" colspan="1">215 (84.7)</td><td valign="top" colspan="1" align="left" rowspan="1">57 (89.1)</td><td valign="top" align="left" rowspan="1" colspan="1">51 (82.3)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Patch, median (IQR) weeks NRT provided</td><td valign="top" align="left" rowspan="1" colspan="1">12.0 (4-20)</td><td valign="top" align="left" rowspan="1" colspan="1">10.0 (4-20)</td><td rowspan="3" valign="middle" align="left" colspan="1">.55</td><td valign="top" align="left" rowspan="1" colspan="1">10.0 (6-18)</td><td valign="top" align="left" rowspan="1" colspan="1">12.0 (4-18)</td><td rowspan="3" valign="middle" align="left" colspan="1">.32</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Lozenge, median (IQR) weeks NRT provided</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (2-10)</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (2-8)</td><td valign="top" colspan="1" align="left" rowspan="1">4.0 (2-12)</td><td valign="top" align="left" rowspan="1" colspan="1">5.0 (2-12)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Gum, median (IQR) weeks NRT provided</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (2-8)</td><td valign="top" align="left" rowspan="1" colspan="1">4.0 (2-8)</td><td valign="top" colspan="1" align="left" rowspan="1">6.0 (2-22)</td><td valign="top" align="left" rowspan="1" colspan="1">6.0 (2-10)</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Nicotine spray or inhaler<sup>a,b</sup></td><td valign="top" align="left" rowspan="1" colspan="1">17 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">34 (13.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.01</td><td valign="top" align="left" rowspan="1" colspan="1">2 (3.1)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Bupropion<sup>a,b</sup></td><td valign="top" align="left" rowspan="1" colspan="1">17 (6.6)</td><td valign="top" align="left" rowspan="1" colspan="1">32 (12.6)</td><td valign="top" align="left" rowspan="1" colspan="1">.02</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">1.0</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Varenicline<sup>a,b</sup></td><td valign="top" align="left" rowspan="1" colspan="1">19 (7.4)</td><td valign="top" align="left" rowspan="1" colspan="1">39 (15.4)</td><td valign="top" align="left" rowspan="1" colspan="1">.01</td><td valign="top" align="left" rowspan="1" colspan="1">1 (1.6)</td><td valign="top" align="left" rowspan="1" colspan="1">7 (11.3)</td><td valign="top" align="left" rowspan="1" colspan="1">.03</td></tr><tr><td valign="top" align="left" scope="row" rowspan="1" colspan="1"> Any of the 4 prescription medications<sup>b</sup></td><td valign="top" align="left" rowspan="1" colspan="1">48 (18.8)</td><td valign="top" align="left" rowspan="1" colspan="1">86 (33.9)</td><td valign="top" align="left" rowspan="1" colspan="1">&lt;.001</td><td valign="top" align="left" rowspan="1" colspan="1">4 (6.3)</td><td valign="top" align="left" rowspan="1" colspan="1">9 (14.5)</td><td valign="top" align="left" rowspan="1" colspan="1">.15</td></tr></tbody></table><table-wrap-foot><p>Abbreviations: NRT, nicotine replacement therapy; TLC, tobacco longitudinal care; TLC + MTM, tobacco longitudinal care&#8201;with medication therapy management.</p><fn id="zoi230858t3n1"><label>
<sup>a</sup>
</label><p>Current usage was assessed during the 6 data collection calls.</p></fn><fn id="zoi230858t3n2"><label>
<sup>b</sup>
</label><p>Ever during 12 months of treatment.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec id="H1-4-ZOI230858"><title>Discussion</title><p>The purpose of this SMART was to generate data to select components for an evidence-based adaptive intervention for smoking cessation treatment in the LCS setting. Among participants who did not respond to the initial TLC treatment, there were no significant differences in long-term or short-term abstinence between TLC with or without the availability of prescription medications. Among participants who did respond to the initial TLC treatment, results suggested that TLC was more effective with at least monthly contact than quarterly contact, but the difference was not statistically significant. Clinically meaningful long-term quit rates were observed across TLC intervention groups. Based on the findings from these primary analyses, TLC was most effective when implemented without modification in the LCS setting.</p><p>Findings from PLUTO inform how to design effective smoking cessation programs in the LCS setting. Based on the primary analyses, there is no evidence to suggest that setting up a referral program for participants to see a pharmacist for MTM (and possible prescription medications for smoking cessation) would yield much benefit. This may have implications for resource allocation because combination NRT is available over the counter and can be dispensed by trained staff, which is less resource intensive than providing prescription medications that require licensed clinicians. There are several potential explanations for these findings. Among early treatment nonresponders, only 39% of participants completed at least 1 MTM visit. Baseline characteristics show that most participants had previously tried prescription medications; perhaps lack of prior success with medications influenced this decision. While prescription medication use was higher in TLC with MTM than in TLC, a number of participants (18.8% of those not randomized to MTM) accessed these medications outside the study (eg, through their health care clinician). Additionally, most participants used considerable amounts of combination NRT, and availability of prescription medications might not have provided important benefit in this context. This could be because coaches promoted combination NRT, it was free of cost, and/or combination NRT is equally effective to prescription medications. However, this finding may not be generalized to populations with limited access to care and prescription medications. Future research should assess whether there are subgroups who would benefit from referral to MTM to access prescription medications.</p><p>The comparison of TLC and Quarterly TLC for early responders suggest monthly follow-up confers long-term cessation advantage. The estimated difference of 14% in abstinence rates was not statistically significant, however, it is clinically significant, and this secondary analysis was underpowered. Based on this result, we recommend that clinicians do not step down to quarterly contact among early responders to TLC. It is likely that, even among early treatment responders, attention to relapse prevention, management of smoking lapses, and adjustment of NRT is important.</p><p>The results of PLUTO are important because they support feasibility and utility of using a chronic care model of tobacco treatment that incorporates medications and intensive counseling. Meaningful long-term quit rates (24.4%, 6-month prolonged abstinence) and short-term quit rates (36.1%, 7-day point prevalence abstinence) were observed overall across TLC groups and these rates compare favorably with other smoking cessation trials in the LCS setting. For example, Taylor et al<sup><xref rid="zoi230858r30" ref-type="bibr">30</xref></sup> tested a short-term (3-month duration) intensive telephone care intervention and found significant effects on abstinence at 3 months that disappeared at longer term follow-up with self-reported 7-day abstinence rates of 9% to 10% at 6 months. In 2 other SCALE trials, Foley et al<sup><xref rid="zoi230858r31" ref-type="bibr">31</xref></sup> reported 7-day abstinence rates of 13% at 6 months, and Tremblay et al<sup><xref rid="zoi230858r32" ref-type="bibr">32</xref></sup> reported 30-day abstinence rates of 13% to 14%. Clinical observational studies have reported quit rates in the LCS setting of 9% to 14%.<sup><xref rid="zoi230858r33" ref-type="bibr">33</xref>,<xref rid="zoi230858r34" ref-type="bibr">34</xref>,<xref rid="zoi230858r35" ref-type="bibr">35</xref></sup> Modeling studies support that integrating tobacco treatment with LCS yields cost-benefits of similar magnitude of LCS itself; for example, adding a tobacco cessation intervention with an effectiveness of 15% results in equivalent life-years gained as increasing LCS uptake from 30% to 100%.<sup><xref rid="zoi230858r36" ref-type="bibr">36</xref></sup> The quit rates observed in PLUTO suggest that the investment of resources to adopt a chronic care model in the LCS setting would be effective and cost-effective. Future research is needed to identify effective implementation strategies to promote adoption and integration of tobacco treatment into the LCS setting.<sup><xref rid="zoi230858r31" ref-type="bibr">31</xref></sup> PLUTO findings are also consistent with a recent systematic review that concluded that smoking cessation interventions delivering combination counseling and medications can be successfully implemented in the LCS setting and observed that more intensive interventions are likely to be more effective than less intensive interventions.<sup><xref rid="zoi230858r37" ref-type="bibr">37</xref></sup></p><sec id="H2-11-ZOI230858"><title>Limitations</title><p>This study has limitations. The primary analysis was adequately powered, but the sample size is relatively small for some secondary outcomes. The smoking abstinence data are self-reported; however, the biochemical verification data available do not suggest a difference in misreport by randomized comparison groups. Because the participant cohort was in the Midwest and predominantly White individuals, findings may have limited generalizability to racially and ethnically minoritized populations.</p></sec></sec><sec id="H1-5-ZOI230858"><title>Conclusions</title><p>In this SMART clinical trial, offering a referral program to MTM along with TLC for patients continuing to smoke did not offer additional benefit. This trial supports the feasibility and use of integrating longitudinal tobacco cessation care into the LCS setting. Long-term smoking abstinence rates for longitudinal care are higher than abstinence rates observed in shorter interventions and indicate the value of taking a longitudinal or chronic care approach to tobacco cessation. Findings also show that patients undergoing LCS who smoke accept TLC, as evidenced by their completion of a relatively large number of calls over a year-long period. Health systems should consider integrating longitudinal tobacco cessation care into the LCS setting.</p></sec></body><back><ref-list id="REF-ZOI230858"><title>References</title><ref id="zoi230858r1"><label>1</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Aberle</surname><given-names>DR</given-names></string-name>, <string-name name-style="western"><surname>Adams</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Berg</surname><given-names>CD</given-names></string-name>, <etal/>; <collab>National Lung Screening Trial Research Team</collab></person-group>. <article-title>Reduced lung-cancer mortality with low-dose computed tomographic screening</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>365</volume>(<issue>5</issue>):<fpage>395</fpage>-<lpage>409</lpage>. doi:<pub-id pub-id-type="doi">10.1056/NEJMoa1102873</pub-id><pub-id pub-id-type="pmid">21714641</pub-id><pub-id pub-id-type="pmcid">PMC4356534</pub-id></mixed-citation></ref><ref id="zoi230858r2"><label>2</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Humphrey</surname><given-names>LL</given-names></string-name>, <string-name name-style="western"><surname>Deffebach</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Pappas</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>Screening for lung cancer with low-dose computed tomography: a systematic review to update the US Preventive Services Task Force recommendation</article-title>. <source>Ann Intern Med</source>. <year>2013</year>;<volume>159</volume>(<issue>6</issue>):<fpage>411</fpage>-<lpage>420</lpage>. doi:<pub-id pub-id-type="doi">10.7326/0003-4819-159-6-201309170-00690</pub-id><pub-id pub-id-type="pmid">23897166</pub-id></mixed-citation></ref><ref id="zoi230858r3"><label>3</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bach</surname><given-names>PB</given-names></string-name>, <string-name name-style="western"><surname>Mirkin</surname><given-names>JN</given-names></string-name>, <string-name name-style="western"><surname>Oliver</surname><given-names>TK</given-names></string-name>, <etal/></person-group>. <article-title>Benefits and harms of CT screening for lung cancer: a systematic review</article-title>. <source>JAMA</source>. <year>2012</year>;<volume>307</volume>(<issue>22</issue>):<fpage>2418</fpage>-<lpage>2429</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2012.5521</pub-id><pub-id pub-id-type="pmid">22610500</pub-id><pub-id pub-id-type="pmcid">PMC3709596</pub-id></mixed-citation></ref><ref id="zoi230858r4"><label>4</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Moyer</surname><given-names>VA</given-names></string-name>; <collab>U.S. Preventive Services Task Force</collab></person-group>. <article-title>Screening for lung cancer: US Preventive Services Task Force recommendation statement</article-title>. <source>Ann Intern Med</source>. <year>2014</year>;<volume>160</volume>(<issue>5</issue>):<fpage>330</fpage>-<lpage>338</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M13-2771</pub-id><pub-id pub-id-type="pmid">24378917</pub-id></mixed-citation></ref><ref id="zoi230858r5"><label>5</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wender</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Fontham</surname><given-names>ETH</given-names></string-name>, <string-name name-style="western"><surname>Barrera</surname><given-names>E</given-names><suffix>Jr</suffix></string-name>, <etal/></person-group>. <article-title>American Cancer Society lung cancer screening guidelines</article-title>. <source>CA Cancer J Clin</source>. <year>2013</year>;<volume>63</volume>(<issue>2</issue>):<fpage>107</fpage>-<lpage>117</lpage>. doi:<pub-id pub-id-type="doi">10.3322/caac.21172</pub-id><pub-id pub-id-type="pmid">23315954</pub-id><pub-id pub-id-type="pmcid">PMC3632634</pub-id></mixed-citation></ref><ref id="zoi230858r6"><label>6</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Wood</surname><given-names>DE</given-names></string-name>, <string-name name-style="western"><surname>Eapen</surname><given-names>GA</given-names></string-name>, <string-name name-style="western"><surname>Ettinger</surname><given-names>DS</given-names></string-name>, <etal/></person-group>. <article-title>Lung cancer screening</article-title>. <source>J Natl Compr Canc Netw</source>. <year>2012</year>;<volume>10</volume>(<issue>2</issue>):<fpage>240</fpage>-<lpage>265</lpage>. doi:<pub-id pub-id-type="doi">10.6004/jnccn.2012.0022</pub-id><pub-id pub-id-type="pmid">22308518</pub-id><pub-id pub-id-type="pmcid">PMC6467530</pub-id></mixed-citation></ref><ref id="zoi230858r7"><label>7</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Detterbeck</surname><given-names>FC</given-names></string-name>, <string-name name-style="western"><surname>Mazzone</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Naidich</surname><given-names>DP</given-names></string-name>, <string-name name-style="western"><surname>Bach</surname><given-names>PB</given-names></string-name></person-group>. <article-title>Screening for lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines</article-title>. <source>Chest</source>. <year>2013</year>;<volume>143</volume>(<issue>5 Suppl</issue>):<fpage>e78S</fpage>-<lpage>92S</lpage>. doi:<pub-id pub-id-type="doi">10.1378/chest.12-2350</pub-id><pub-id pub-id-type="pmid">23649455</pub-id><pub-id pub-id-type="pmcid">PMC3749713</pub-id></mixed-citation></ref><ref id="zoi230858r8"><label>8</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Meza</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname><given-names>J</given-names></string-name>, <string-name name-style="western"><surname>Jimenez-Mendoza</surname><given-names>E</given-names></string-name>, <etal/></person-group>. <article-title>National Cancer Institute Smoking Cessation at lung examination trials brief report: baseline characteristics and comparison with the US general population of lung cancer screening-eligible patients</article-title>. <source>JTO Clin Res Rep</source>. <year>2022</year>;<volume>3</volume>(<issue>7</issue>):<elocation-id>100352</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.jtocrr.2022.100352</pub-id><pub-id pub-id-type="pmid">35815319</pub-id><pub-id pub-id-type="pmcid">PMC9257405</pub-id></mixed-citation></ref><ref id="zoi230858r9"><label>9</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Krist</surname><given-names>AH</given-names></string-name>, <string-name name-style="western"><surname>Davidson</surname><given-names>KW</given-names></string-name>, <string-name name-style="western"><surname>Mangione</surname><given-names>CM</given-names></string-name>, <etal/>; <collab>US Preventive Services Task Force</collab></person-group>. <article-title>Screening for lung cancer: US Preventive Services Task Force recommendation statement</article-title>. <source>JAMA</source>. <year>2021</year>;<volume>325</volume>(<issue>10</issue>):<fpage>962</fpage>-<lpage>970</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2021.1117</pub-id><pub-id pub-id-type="pmid">33687470</pub-id></mixed-citation></ref><ref id="zoi230858r10"><label>10</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Sahar</surname><given-names>L</given-names></string-name>, <string-name name-style="western"><surname>Douangchai Wills</surname><given-names>VL</given-names></string-name>, <string-name name-style="western"><surname>Liu</surname><given-names>KKA</given-names></string-name>, <etal/></person-group>. <article-title>Geographic access to lung cancer screening among eligible adults living in rural and urban environments in the United States</article-title>. <source>Cancer</source>. <year>2022</year>;<volume>128</volume>(<issue>8</issue>):<fpage>1584</fpage>-<lpage>1594</lpage>. doi:<pub-id pub-id-type="doi">10.1002/cncr.33996</pub-id><pub-id pub-id-type="pmid">35167123</pub-id></mixed-citation></ref><ref id="zoi230858r11"><label>11</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Heiden</surname><given-names>BT</given-names></string-name>, <string-name name-style="western"><surname>Engelhardt</surname><given-names>KE</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>C</given-names></string-name>, <etal/></person-group>. <article-title>Prevalence of cigarette and e-cigarette use among U.S. adults eligible for lung cancer screening based on updated USPSTF guidelines</article-title>. <source>Cancer Epidemiol</source>. <year>2022</year>;<volume>76</volume>:<elocation-id>102079</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.canep.2021.102079</pub-id><pub-id pub-id-type="pmid">34894590</pub-id></mixed-citation></ref><ref id="zoi230858r12"><label>12</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tanner</surname><given-names>NT</given-names></string-name>, <string-name name-style="western"><surname>Kanodra</surname><given-names>NM</given-names></string-name>, <string-name name-style="western"><surname>Gebregziabher</surname><given-names>M</given-names></string-name>, <etal/></person-group>. <article-title>The association between smoking abstinence and mortality in the National Lung Screening trial</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2016</year>;<volume>193</volume>(<issue>5</issue>):<fpage>534</fpage>-<lpage>541</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201507-1420OC</pub-id><pub-id pub-id-type="pmid">26502000</pub-id></mixed-citation></ref><ref id="zoi230858r13"><label>13</label><mixed-citation publication-type="book"><person-group><string-name name-style="western"><surname>Fiore</surname><given-names>MCJC</given-names></string-name>, <string-name name-style="western"><surname>Baker</surname><given-names>TB</given-names></string-name>, <etal/></person-group>. <source>Treating Tobacco Use and Dependence: 2008 Update. Clinical Practice Guideline</source>. <publisher-name>U.S. Department of Health and Human Services. Public Health Service</publisher-name>; <year>2008</year>.</mixed-citation></ref><ref id="zoi230858r14"><label>14</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Iaccarino</surname><given-names>JM</given-names></string-name>, <string-name name-style="western"><surname>Duran</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Slatore</surname><given-names>CG</given-names></string-name>, <string-name name-style="western"><surname>Wiener</surname><given-names>RS</given-names></string-name>, <string-name name-style="western"><surname>Kathuria</surname><given-names>H</given-names></string-name></person-group>. <article-title>Combining smoking cessation interventions with LDCT lung cancer screening: a systematic review</article-title>. <source>Prev Med</source>. <year>2019</year>;<volume>121</volume>:<fpage>24</fpage>-<lpage>32</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.ypmed.2019.02.016</pub-id><pub-id pub-id-type="pmid">30753860</pub-id></mixed-citation></ref><ref id="zoi230858r15"><label>15</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Moldovanu</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>de Koning</surname><given-names>HJ</given-names></string-name>, <string-name name-style="western"><surname>van der Aalst</surname><given-names>CM</given-names></string-name></person-group>. <article-title>Lung cancer screening and smoking cessation efforts</article-title>. <source>Transl Lung Cancer Res</source>. <year>2021</year>;<volume>10</volume>(<issue>2</issue>):<fpage>1099</fpage>-<lpage>1109</lpage>. doi:<pub-id pub-id-type="doi">10.21037/tlcr-20-899</pub-id><pub-id pub-id-type="pmid">33718048</pub-id><pub-id pub-id-type="pmcid">PMC7947402</pub-id></mixed-citation></ref><ref id="zoi230858r16"><label>16</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Burns</surname><given-names>RJ</given-names></string-name>, <string-name name-style="western"><surname>Rothman</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Lindgren</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Vock</surname><given-names>DM</given-names></string-name>, <string-name name-style="western"><surname>Joseph</surname><given-names>AM</given-names></string-name></person-group>. <article-title>Longitudinal care improves cessation in smokers who do not initially respond to treatment by increasing cessation self-efficacy, satisfaction, and readiness to quit: a mediated moderation analysis</article-title>. <source>Ann Behav Med</source>. <year>2016</year>;<volume>50</volume>(<issue>1</issue>):<fpage>58</fpage>-<lpage>69</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s12160-015-9732-1</pub-id><pub-id pub-id-type="pmid">26373657</pub-id><pub-id pub-id-type="pmcid">PMC4744132</pub-id></mixed-citation></ref><ref id="zoi230858r17"><label>17</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Joseph</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Fu</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Lindgren</surname><given-names>B</given-names></string-name>, <etal/></person-group>. <article-title>Chronic disease management for tobacco dependence: a randomized, controlled trial</article-title>. <source>Arch Intern Med</source>. <year>2011</year>;<volume>171</volume>(<issue>21</issue>):<fpage>1894</fpage>-<lpage>1900</lpage>. doi:<pub-id pub-id-type="doi">10.1001/archinternmed.2011.500</pub-id><pub-id pub-id-type="pmid">22123795</pub-id><pub-id pub-id-type="pmcid">PMC4110895</pub-id></mixed-citation></ref><ref id="zoi230858r18"><label>18</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Bodenheimer</surname><given-names>T</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>EH</given-names></string-name>, <string-name name-style="western"><surname>Grumbach</surname><given-names>K</given-names></string-name></person-group>. <article-title>Improving primary care for patients with chronic illness</article-title>. <source>JAMA</source>. <year>2002</year>;<volume>288</volume>(<issue>14</issue>):<fpage>1775</fpage>-<lpage>1779</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.288.14.1775</pub-id><pub-id pub-id-type="pmid">12365965</pub-id></mixed-citation></ref><ref id="zoi230858r19"><label>19</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Glasgow</surname><given-names>RE</given-names></string-name>, <string-name name-style="western"><surname>Orleans</surname><given-names>CT</given-names></string-name>, <string-name name-style="western"><surname>Wagner</surname><given-names>EH</given-names></string-name></person-group>. <article-title>Does the chronic care model serve also as a template for improving prevention?</article-title><source>Milbank Q</source>. <year>2001</year>;<volume>79</volume>(<issue>4</issue>):<fpage>579</fpage>-<lpage>612, iv-v</lpage>. doi:<pub-id pub-id-type="doi">10.1111/1468-0009.00222</pub-id><pub-id pub-id-type="pmid">11789118</pub-id><pub-id pub-id-type="pmcid">PMC2751207</pub-id></mixed-citation></ref><ref id="zoi230858r20"><label>20</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Fu</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Rothman</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Vock</surname><given-names>DM</given-names></string-name>, <etal/></person-group>. <article-title>Program for lung cancer screening and tobacco cessation: study protocol of a sequential, multiple assignment, randomized trial</article-title>. <source>Contemp Clin Trials</source>. <year>2017</year>;<volume>60</volume>:<fpage>86</fpage>-<lpage>95</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.cct.2017.07.002</pub-id><pub-id pub-id-type="pmid">28687349</pub-id><pub-id pub-id-type="pmcid">PMC5558455</pub-id></mixed-citation></ref><ref id="zoi230858r21"><label>21</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Joseph</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Rothman</surname><given-names>AJ</given-names></string-name>, <string-name name-style="western"><surname>Almirall</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Lung cancer screening and smoking cessation clinical trials: SCALE (smoking cessation within the context of lung cancer screening) collaboration</article-title>. <source>Am J Respir Crit Care Med</source>. <year>2018</year>;<volume>197</volume>(<issue>2</issue>):<fpage>172</fpage>-<lpage>182</lpage>. doi:<pub-id pub-id-type="doi">10.1164/rccm.201705-0909CI</pub-id><pub-id pub-id-type="pmid">28977754</pub-id><pub-id pub-id-type="pmcid">PMC5768904</pub-id></mixed-citation></ref><ref id="zoi230858r22"><label>22</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Almirall</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Nahum-Shani</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Sherwood</surname><given-names>NE</given-names></string-name>, <string-name name-style="western"><surname>Murphy</surname><given-names>SA</given-names></string-name></person-group>. <article-title>Introduction to SMART designs for the development of adaptive interventions: with application to weight loss research</article-title>. <source>Transl Behav Med</source>. <year>2014</year>;<volume>4</volume>(<issue>3</issue>):<fpage>260</fpage>-<lpage>274</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s13142-014-0265-0</pub-id><pub-id pub-id-type="pmid">25264466</pub-id><pub-id pub-id-type="pmcid">PMC4167891</pub-id></mixed-citation></ref><ref id="zoi230858r23"><label>23</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Murphy</surname><given-names>SA</given-names></string-name></person-group>. <article-title>An experimental design for the development of adaptive treatment strategies</article-title>. <source>Stat Med</source>. <year>2005</year>;<volume>24</volume>(<issue>10</issue>):<fpage>1455</fpage>-<lpage>1481</lpage>. doi:<pub-id pub-id-type="doi">10.1002/sim.2022</pub-id><pub-id pub-id-type="pmid">15586395</pub-id></mixed-citation></ref><ref id="zoi230858r24"><label>24</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Nahum-Shani</surname><given-names>I</given-names></string-name>, <string-name name-style="western"><surname>Qian</surname><given-names>M</given-names></string-name>, <string-name name-style="western"><surname>Almirall</surname><given-names>D</given-names></string-name>, <etal/></person-group>. <article-title>Experimental design and primary data analysis methods for comparing adaptive interventions</article-title>. <source>Psychol Methods</source>. <year>2012</year>;<volume>17</volume>(<issue>4</issue>):<fpage>457</fpage>-<lpage>477</lpage>. doi:<pub-id pub-id-type="doi">10.1037/a0029372</pub-id><pub-id pub-id-type="pmid">23025433</pub-id><pub-id pub-id-type="pmcid">PMC3825557</pub-id></mixed-citation></ref><ref id="zoi230858r25"><label>25</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Kidwell</surname><given-names>KM</given-names></string-name>, <string-name name-style="western"><surname>Almirall</surname><given-names>D</given-names></string-name></person-group>. <article-title>Sequential, multiple assignment, randomized trial designs</article-title>. <source>JAMA</source>. <year>2023</year>;<volume>329</volume>(<issue>4</issue>):<fpage>336</fpage>-<lpage>337</lpage>. doi:<pub-id pub-id-type="doi">10.1001/jama.2022.24324</pub-id><pub-id pub-id-type="pmid">36692577</pub-id><pub-id pub-id-type="pmcid">PMC10061579</pub-id></mixed-citation></ref><ref id="zoi230858r26"><label>26</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Piper</surname><given-names>ME</given-names></string-name>, <string-name name-style="western"><surname>Bullen</surname><given-names>C</given-names></string-name>, <string-name name-style="western"><surname>Krishnan-Sarin</surname><given-names>S</given-names></string-name>, <etal/></person-group>. <article-title>Defining and measuring abstinence in clinical trials of smoking cessation interventions: an updated review</article-title>. <source>Nicotine Tob Res</source>. <year>2020</year>;<volume>22</volume>(<issue>7</issue>):<fpage>1098</fpage>-<lpage>1106</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ntr/ntz110</pub-id><pub-id pub-id-type="pmid">31271211</pub-id><pub-id pub-id-type="pmcid">PMC9633719</pub-id></mixed-citation></ref><ref id="zoi230858r27"><label>27</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Siu</surname><given-names>AL</given-names></string-name>, <string-name name-style="western"><surname>Force</surname><given-names>USPST</given-names></string-name>; <collab>U.S. Preventive Services Task Force</collab></person-group>. <article-title>Behavioral and pharmacotherapy interventions for tobacco smoking cessation in adults, including pregnant women: US Preventive Services Task Force recommendation statement</article-title>. <source>Ann Intern Med</source>. <year>2015</year>;<volume>163</volume>(<issue>8</issue>):<fpage>622</fpage>-<lpage>634</lpage>. doi:<pub-id pub-id-type="doi">10.7326/M15-2023</pub-id><pub-id pub-id-type="pmid">26389730</pub-id></mixed-citation></ref><ref id="zoi230858r28"><label>28</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Meredith</surname><given-names>SE</given-names></string-name>, <string-name name-style="western"><surname>Robinson</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Erb</surname><given-names>P</given-names></string-name>, <etal/></person-group>. <article-title>A mobile-phone-based breath carbon monoxide meter to detect cigarette smoking</article-title>. <source>Nicotine Tob Res</source>. <year>2014</year>;<volume>16</volume>(<issue>6</issue>):<fpage>766</fpage>-<lpage>773</lpage>. doi:<pub-id pub-id-type="doi">10.1093/ntr/ntt275</pub-id><pub-id pub-id-type="pmid">24470633</pub-id><pub-id pub-id-type="pmcid">PMC4031569</pub-id></mixed-citation></ref><ref id="zoi230858r29"><label>29</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Schulz</surname><given-names>KF</given-names></string-name>, <string-name name-style="western"><surname>Altman</surname><given-names>DG</given-names></string-name>, <string-name name-style="western"><surname>Moher</surname><given-names>D</given-names></string-name>, <string-name name-style="western"><surname>Group</surname><given-names>C</given-names></string-name>; <collab>CONSORT Group</collab></person-group>. <article-title>CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials</article-title>. <source>Trials</source>. <year>2010</year>;<volume>11</volume>:<fpage>32</fpage>. doi:<pub-id pub-id-type="doi">10.1186/1745-6215-11-32</pub-id><pub-id pub-id-type="pmid">20334632</pub-id><pub-id pub-id-type="pmcid">PMC2857832</pub-id></mixed-citation></ref><ref id="zoi230858r30"><label>30</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Taylor</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Williams</surname><given-names>RM</given-names></string-name>, <string-name name-style="western"><surname>Li</surname><given-names>T</given-names></string-name>, <etal/>; <collab>Georgetown Lung Screening, Tobacco, and Health Trial</collab></person-group>. <article-title>A randomized trial of telephone-based smoking cessation treatment in the lung cancer screening setting</article-title>. <source>J Natl Cancer Inst</source>. <year>2022</year>;<volume>114</volume>(<issue>10</issue>):<fpage>1410</fpage>-<lpage>1419</lpage>. doi:<pub-id pub-id-type="doi">10.1093/jnci/djac127</pub-id><pub-id pub-id-type="pmid">35818122</pub-id><pub-id pub-id-type="pmcid">PMC9552302</pub-id></mixed-citation></ref><ref id="zoi230858r31"><label>31</label><mixed-citation publication-type="webpage"><person-group><string-name name-style="western"><surname>Foley</surname><given-names>KL</given-names></string-name>, <string-name name-style="western"><surname>Dressler</surname><given-names>EV</given-names></string-name>, <string-name name-style="western"><surname>Weaver</surname><given-names>KE</given-names></string-name>, <etal/></person-group>. <article-title>The optimizing lung screening trial: multicenter randomized effectiveness implementation trial to increase tobacco use cessation for individuals undergoing lung screening</article-title>. <source>Chest</source>. Published online March 15, 2023. doi:<pub-id pub-id-type="doi">10.1016/j.chest.2023.03.013</pub-id><pub-id pub-id-type="pmcid">PMC10410244</pub-id><pub-id pub-id-type="pmid">36931460</pub-id></mixed-citation></ref><ref id="zoi230858r32"><label>32</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Tremblay</surname><given-names>A</given-names></string-name>, <string-name name-style="western"><surname>Taghizadeh</surname><given-names>N</given-names></string-name>, <string-name name-style="western"><surname>Huang</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>A randomized controlled study of integrated smoking cessation in a lung cancer screening program</article-title>. <source>J Thorac Oncol</source>. <year>2019</year>;<volume>14</volume>(<issue>9</issue>):<fpage>1528</fpage>-<lpage>1537</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jtho.2019.04.024</pub-id><pub-id pub-id-type="pmid">31077790</pub-id></mixed-citation></ref><ref id="zoi230858r33"><label>33</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Fu</surname><given-names>SS</given-names></string-name>, <string-name name-style="western"><surname>Melzer</surname><given-names>AC</given-names></string-name>, <string-name name-style="western"><surname>Fabbrini</surname><given-names>AE</given-names></string-name>, <etal/></person-group>. <article-title>Association of invitation to lung cancer screening and tobacco use outcomes in a VA demonstration project</article-title>. <source>Prev Med Rep</source>. <year>2019</year>;<volume>16</volume>:<elocation-id>101023</elocation-id>. doi:<pub-id pub-id-type="doi">10.1016/j.pmedr.2019.101023</pub-id><pub-id pub-id-type="pmid">31788415</pub-id><pub-id pub-id-type="pmcid">PMC6879990</pub-id></mixed-citation></ref><ref id="zoi230858r34"><label>34</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Heffner</surname><given-names>JL</given-names></string-name>, <string-name name-style="western"><surname>Coggeshall</surname><given-names>S</given-names></string-name>, <string-name name-style="western"><surname>Wheat</surname><given-names>CL</given-names></string-name>, <etal/></person-group>. <article-title>Receipt of tobacco treatment and 1-year smoking cessation rates following lung cancer screening in the Veterans Health Administration</article-title>. <source>J Gen Intern Med</source>. <year>2022</year>;<volume>37</volume>(<issue>7</issue>):<fpage>1704</fpage>-<lpage>1712</lpage>. doi:<pub-id pub-id-type="doi">10.1007/s11606-021-07011-0</pub-id><pub-id pub-id-type="pmid">34282533</pub-id><pub-id pub-id-type="pmcid">PMC9130430</pub-id></mixed-citation></ref><ref id="zoi230858r35"><label>35</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Williams</surname><given-names>PJ</given-names></string-name>, <string-name name-style="western"><surname>Philip</surname><given-names>KEJ</given-names></string-name>, <string-name name-style="western"><surname>Gill</surname><given-names>NK</given-names></string-name>, <etal/></person-group>. <article-title>Immediate, remote smoking cessation intervention in participants undergoing a targeted lung health check: quit smoking lung health intervention trial, a randomized controlled trial</article-title>. <source>Chest</source>. <year>2023</year>;<volume>163</volume>(<issue>2</issue>):<fpage>455</fpage>-<lpage>463</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.chest.2022.06.048</pub-id><pub-id pub-id-type="pmid">35932889</pub-id><pub-id pub-id-type="pmcid">PMC9899638</pub-id></mixed-citation></ref><ref id="zoi230858r36"><label>36</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Meza</surname><given-names>R</given-names></string-name>, <string-name name-style="western"><surname>Cao</surname><given-names>P</given-names></string-name>, <string-name name-style="western"><surname>Jeon</surname><given-names>J</given-names></string-name>, <etal/></person-group>. <article-title>Impact of joint lung cancer screening and cessation interventions under the new recommendations of the US Preventive Services Task Force</article-title>. <source>J Thorac Oncol</source>. <year>2022</year>;<volume>17</volume>(<issue>1</issue>):<fpage>160</fpage>-<lpage>166</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.jtho.2021.09.011</pub-id><pub-id pub-id-type="pmid">34648947</pub-id><pub-id pub-id-type="pmcid">PMC8692396</pub-id></mixed-citation></ref><ref id="zoi230858r37"><label>37</label><mixed-citation publication-type="journal"><person-group><string-name name-style="western"><surname>Pi&#241;eiro</surname><given-names>B</given-names></string-name>, <string-name name-style="western"><surname>Simmons</surname><given-names>VN</given-names></string-name>, <string-name name-style="western"><surname>Palmer</surname><given-names>AM</given-names></string-name>, <string-name name-style="western"><surname>Correa</surname><given-names>JB</given-names></string-name>, <string-name name-style="western"><surname>Brandon</surname><given-names>TH</given-names></string-name></person-group>. <article-title>Smoking cessation interventions within the context of low-dose computed tomography lung cancer screening: a systematic review</article-title>. <source>Lung Cancer</source>. <year>2016</year>;<volume>98</volume>:<fpage>91</fpage>-<lpage>98</lpage>. doi:<pub-id pub-id-type="doi">10.1016/j.lungcan.2016.05.028</pub-id><pub-id pub-id-type="pmid">27393513</pub-id></mixed-citation></ref></ref-list><notes notes-type="supplementary-material" id="note-ZOI230858-1"><supplementary-material id="note-ZOI230858-1-s" position="float" content-type="local-data" orientation="portrait"><label>Supplement 1.</label><caption><p>
Trial Protocol and Statistical Analysis Plan
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2329903-s001.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 2.</label><caption><p><bold>eTable.</bold> Observed and Adjusted Abstinence Rates and Sensitivity Analyses for Early Treatment Responders</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2329903-s002.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material><supplementary-material position="float" content-type="local-data" orientation="portrait"><label>Supplement 3.</label><caption><p>
Data Sharing Statement
</p></caption><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="jamanetwopen-e2329903-s003.pdf" position="float" orientation="portrait"><caption><p>Click here for additional data file.</p></caption></media></supplementary-material></notes></back></article></pmc-articleset>